Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Dual roles for lysine 490 of promyelocytic leukemia protein in the transactivation of glucocorticoid receptor-interacting protein 1.

Liu ST, Lu GY, Hsu YJ, Chang LC, Ho CL, Huang SM.

Biochim Biophys Acta. 2013 Aug;1833(8):1799-810. doi: 10.1016/j.bbamcr.2013.03.015. Epub 2013 Mar 28.

2.
3.

The glucocorticoid receptor interacting protein 1 (GRIP1) localizes in discrete nuclear foci that associate with ND10 bodies and are enriched in components of the 26S proteasome.

Baumann CT, Ma H, Wolford R, Reyes JC, Maruvada P, Lim C, Yen PM, Stallcup MR, Hager GL.

Mol Endocrinol. 2001 Apr;15(4):485-500.

PMID:
11266502
4.

Modulation of the Zac1's transactivation and coactivation functions via PML and Daxx within distinct subcellular localizations.

Ho CL, Huang YC, Tai CK, Liu ST, Wang JK, Wang WM, Huang SM.

Int J Biochem Cell Biol. 2010 Jun;42(6):902-10. doi: 10.1016/j.biocel.2010.01.020. Epub 2010 Jan 25.

PMID:
20097304
6.

Contribution of the C-terminal regions of promyelocytic leukemia protein (PML) isoforms II and V to PML nuclear body formation.

Geng Y, Monajembashi S, Shao A, Cui D, He W, Chen Z, Hemmerich P, Tang J.

J Biol Chem. 2012 Aug 31;287(36):30729-42. doi: 10.1074/jbc.M112.374769. Epub 2012 Jul 7.

7.

Sumoylation of Daxx regulates IFN-induced growth suppression of B lymphocytes and the hormone receptor-mediated transactivation.

Muromoto R, Ishida M, Sugiyama K, Sekine Y, Oritani K, Shimoda K, Matsuda T.

J Immunol. 2006 Jul 15;177(2):1160-70.

9.

Role of nuclear bodies in apoptosis signalling.

Krieghoff-Henning E, Hofmann TG.

Biochim Biophys Acta. 2008 Nov;1783(11):2185-94. doi: 10.1016/j.bbamcr.2008.07.002. Epub 2008 Jul 16. Review.

10.

PML positively regulates interferon gamma signaling.

El Bougrini J, Dianoux L, Chelbi-Alix MK.

Biochimie. 2011 Mar;93(3):389-98. doi: 10.1016/j.biochi.2010.11.005. Epub 2010 Nov 27.

PMID:
21115099
11.

Requirement of PML SUMO interacting motif for RNF4- or arsenic trioxide-induced degradation of nuclear PML isoforms.

Maroui MA, Kheddache-Atmane S, El Asmi F, Dianoux L, Aubry M, Chelbi-Alix MK.

PLoS One. 2012;7(9):e44949. doi: 10.1371/journal.pone.0044949. Epub 2012 Sep 18.

12.

β-catenin inhibits promyelocytic leukemia protein tumor suppressor function in colorectal cancer cells.

Satow R, Shitashige M, Jigami T, Fukami K, Honda K, Kitabayashi I, Yamada T.

Gastroenterology. 2012 Mar;142(3):572-81. doi: 10.1053/j.gastro.2011.11.041. Epub 2011 Dec 9.

PMID:
22155184
13.

The calcium-responsive transactivator recruits CREB binding protein to nuclear bodies.

Pradhan A, Liu Y.

Neurosci Lett. 2004 Nov 11;370(2-3):191-5.

PMID:
15488321
15.

Physical and functional link of the leukemia-associated factors AML1 and PML.

Nguyen LA, Pandolfi PP, Aikawa Y, Tagata Y, Ohki M, Kitabayashi I.

Blood. 2005 Jan 1;105(1):292-300. Epub 2004 Aug 26.

16.

Selective activation of NFAT by promyelocytic leukemia protein.

Lo YH, Wu CC, Shih HM, Lai MZ.

Oncogene. 2008 Jun 19;27(27):3821-30. doi: 10.1038/onc.2008.2. Epub 2008 Feb 4.

PMID:
18246125
17.

Role of SUMO in RNF4-mediated promyelocytic leukemia protein (PML) degradation: sumoylation of PML and phospho-switch control of its SUMO binding domain dissected in living cells.

Percherancier Y, Germain-Desprez D, Galisson F, Mascle XH, Dianoux L, Estephan P, Chelbi-Alix MK, Aubry M.

J Biol Chem. 2009 Jun 12;284(24):16595-608. doi: 10.1074/jbc.M109.006387. Epub 2009 Apr 20.

18.

AXIN is an essential co-activator for the promyelocytic leukemia protein in p53 activation.

Li Q, He Y, Wei L, Wu X, Wu D, Lin S, Wang Z, Ye Z, Lin SC.

Oncogene. 2011 Mar 10;30(10):1194-204. doi: 10.1038/onc.2010.499. Epub 2010 Nov 8.

PMID:
21057547
19.

The transcription coactivator CBP is a dynamic component of the promyelocytic leukemia nuclear body.

Boisvert FM, Kruhlak MJ, Box AK, Hendzel MJ, Bazett-Jones DP.

J Cell Biol. 2001 Mar 5;152(5):1099-106.

20.

Nucleus accumbens associated 1 is recruited within the promyelocytic leukemia nuclear body through SUMO modification.

Tatemichi Y, Shibazaki M, Yasuhira S, Kasai S, Tada H, Oikawa H, Suzuki Y, Takikawa Y, Masuda T, Maesawa C.

Cancer Sci. 2015 Jul;106(7):848-56. doi: 10.1111/cas.12680. Epub 2015 May 26.

Supplemental Content

Support Center